

Improving the Drug Loading Capacity and Downstream Processing of HPMCAS using Gelucire® 48/16 in Hot-Melt Extrusion



David S. Nakhla^{1*}, Masumi Dave², Nicholas DiFranco², Inayet Ellis²

¹SE Tylose USA Inc., Pharmaceutical Application Laboratory, Paramus, New Jersey-07652, USA

²Gattefossé USA. Pharmaceutical Division, Paramus, NJ 07652, USA

Send correspondence to: David.Nakhla@setyloseusa.com

PURPOSE

- Improving the drug loading capacity and downstream processability of Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS, Shin-Etsu AQOAT®) in hot-melt extrusion-based amorphous solid dispersions (ASDs) is necessary to reduce the pill burden and optimize drug release and tablet properties (1–3).
- In this work, we evaluated the co-processing of a lipid surfactant, Gelucire® 48/16, polyoxyl-32 stearate (G4816) with HPMCAS (ASMMP) in ASD formulations of nifedipine (NIF) and fenofibrate (FF).

METHODS

- Gelucire® 4816 was frozen overnight (- 20 °C) then micronized using a mortar and pestle into fine powder and sieved with a mesh #60 (250 µm).
- NIF or FF were blended with HPMCAS and Gelucire® 48/16 for 10 minutes using Turbula mixer according to **Table 1**.
- HME was conducted using a PHARMA 11 twin-screw extruder (Thermo Fisher, Germany) and the process parameters are presented in **Table 2**.
- Extruded filaments were milled using a hammer-mill (Frewitt, Germany) at 15,000 rpm through a 1 mm sieve and evaluated for particle size distribution (PSD) using a Sympatec® laser diffraction particle size analyzer.
- Milled extrudates were re-milled through a 0.5 mm sieve and compacted into tablets according to the formulation described in **Table 3 and 4**.
- Tablet properties (hardness and disintegration time) were evaluated using an Erweka® hardness and disintegration tester.
- In vitro* drug release testing for NIF tablet formulations was carried out using a USP-II dissolution apparatus (n = 3) in 1000 mL of PBS (pH = 6.8), 75 rpm, 37°C and drug concentration was evaluated using an established HPLC-UV method.
- In vitro* drug release testing for FF tablet formulations was carried out using the same apparatus (n = 3) in 500mL of PBS (pH = 6.8) with 0.025M sodium lauryl sulfate (SLS), 75 rpm, 37 °C and drug concentration was evaluated using an established HPLC-UV method.

Table 1: HME formulations

Ingredients	F1	F2	F3
	(%)	(%)	(%)
NIF	33	20	-
FF	-	-	20
AS-MMP	57	70	70
Gelucire® 48/16	10	10	10
Total	100	100	100

Table 2: HME process parameters

	NIF formulations	FF formulation
Screw design	Standard HME with 2 kneading zones	
Screw speed (rpm)	150	50
Feed rate (g/min)	6	5
Die size (mm)	2	2
Temperature (°C)	Zone 1: 90, Zone 2 – 8: 175	Zone 1: 60, Zone 2 – 8: 160

Table 3: Tablet formulations



Ingredient	Function	(%)
ASD	Enhance solubility	50
MCC (PH-102)	Filler	43
L-HPC (LH-21)	Binder - Disintegrant	5
Compritol 888 ATO	Lubricant	2

Table 4: Tablet properties

Property	Value
Weight (mg)	400
Compaction (kN)	5, 15, 25
Dimensions	10.mm curved face





RESULTS

HME Torque results






- At least **50% reduction in Torque** was observed in NIF and FF HPMCAS-based ASDs formulations co-processed with **Gelucire® 48/16**

Particle size distribution (PSD)






- Adding Gelucire® 48/16 (10%) to FF: AS-MMP (1:4) during HME, resulted in more than 50% reduction in D50 (189 µm vs 520 µm)
- With NIF: AS-MMP (1:2) or (1:4) formulations, adding Gelucire® 48/16 (10%) resulted in modest reduction in D50.

Tablet Hardness



- With FF: AS-MMP (1:4) formulation, adding Gelucire® 48/16 (10%) resulted in a significant increase in average tablet hardness (83 N vs 36 N at 15 kN compaction load)
- With NIF: AS-MMP (1:2) formulation, a 30% increase in tablet hardness was observed with Gelucire® 48/16.
- No significant difference was observed in tablet hardness with and without Gelucire® 48/16 for NIF: AS-MMP (1:4).

In vitro drug release studies



- No significant difference in drug release of FF: AS-MMP (1:4) formulation with & without Gelucire® 48/16 (10%).
- Without Gelucire® 48/16, high drug load of NIF (33%) in the NIF: AS-MMP (1:2) formula, results in drug crystallization after 1 hour, while the lower drug load formulation (20%) results in complete release of NIF (80%).
- Adding Gelucire® 48/16 (10%) to the high drug load formulation, NIF: AS-MMP (1:2), prevents the drug crystallization and results in complete (80%) drug release.

CONCLUSION

- Co-processing of lipid surfactant (10% Gelucire® 48/16) with HPMCAS during HME of high drug load ASDs of NIF and FF significantly reduces the generated torque (at least 50% reduction) resulting in easier extrusion and higher brittleness of the produced filament.
- Milling of the extrudates resulted in significant reduction in particle size D50 and improved tablet hardness.
- Maintenance of supersaturation was achieved with high drug load ASD formulation of NIF: AS-MMP (1:2) with G4816 (10%).
- The study highlights the utility of combining lipid surfactants with HPMCAS-based ASD formulations in HME to improve the processability, downstream processing, tablet hardness and drug release. This can, potentially reduce the pill burden and improve patient compliance with the medication.

REFERENCES

- Nakhla DS, Mishra SM, Lübbert C, Mejia L, Agatovure K, Sauer A. Double action of HPMCAS as a dry binder and precipitation inhibitor in ASD tablet formulations of nifedipine prepared by hot-melt extrusion. IJPX (2026).
- Panigrahi KC, Patra ChN, Jena GK, Ghose D, Jena J, Panda SK, et al. Gelucire®: A versatile polymer for modified release drug delivery system. Futur J Pharm Sci. (2018).
- Mishra SM, Richter M, Mejia L, Sauer A. Downstream Processing of Itraconazole:HPMCAS Amorphous Solid Dispersion: From Hot-Melt Extrudate to Tablet Using a Quality by Design Approach. Pharmaceutics (2022).